# Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus

> **NCT02265744** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 730 (actual)

## Conditions studied

- Lupus

## Interventions

- **DRUG:** BMS-931699
- **DRUG:** Placebo matching BMS-931699

## Key facts

- **NCT ID:** NCT02265744
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-13
- **Primary completion:** 2017-10-26
- **Final completion:** 2017-11-30
- **Target enrollment:** 730 (ACTUAL)
- **Last updated:** 2019-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02265744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02265744, "Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02265744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*